Strides Pharma Science could ride long-term demand for lower-cost medicines, but its heavy exposure to the US and shifting trade and supply-chain rules may make results bumpier than many expect. The biggest question is whether new, more specialised products can offset tougher pricing, tighter regulation, and changing treatment trends.Read more
Strides Pharma Science leans into rising demand for affordable medicines, while pushing into harder-to-make products and using digital tools to reach more patients across markets. The upside comes with real bumps in the road, including tough regulators, price pressure in generics, and heavy reliance on the US for a big slice of sales.Read more
Key Takeaways Strides is achieving stronger margins and growth than expected, driven by portfolio rationalization, operational enhancements, and effective entry into less competitive, higher-margin products. Expansion into differentiated products and emerging markets is reducing risk and supporting sustainable, stable revenue and earnings growth.Read more
No trending discussion available.
Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, and internationally. The company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, gels, powders, solids, ointments, and creams. It also develops branded generics products for the treatment of chronic therapies, including women’s health, central nervous system, cardiovascular, diabetes, dermatology, and probiotics under the Renerve, Unibrol, Combiart, Duotab, and Vitafer brands; and anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for institutional business. The company was formerly known as Strides Shasun Limited and changed its name to Strides Pharma Science Limited in July 2018. The company was incorporated in 1990 and is based in Bengaluru, India.
